ORLANDO (EGMN) - Adding erlotinib to maintenance therapy with bevacizumab delayed disease progression in patients with advanced non-small cell lung cancer in the international phase IIIb ATLAS trial.The median progression-free survival by investigator assessment was 4.76 months for bevacizumab (Avastin) plus erlotinib (Tarceva) and 3.75 months for bevacizumab plus placebo (hazard ratio 0.72, P = .0012), Dr. Vincent Miller reported at the annual meeting of the American Society of Clinical Oncology....